Final Results of an EORTC-GU Cancers Group Randomized Study of Maintenance Bacillus Calmette-Guerin in Intermediate- and High-risk Ta, T1 Papillary Carcinoma of the Urinary Bladder: One-third Dose Versus Full Dose and 1 Year Versus 3 Years of Maintenance

Autor: Cees van de Beek, Aldo V. Bono, Levent Türkeri, Paolo Gontero, George van Andel, Willem Oosterlinck, Sandrine Marreaud, Sandra Collette, Maurizio A. Brausi, Richard J. Sylvester, Jorg R. Oddens, Wolfgang Hoeltl

Publikováno v: European Urology, 63(3), 462-472. Elsevier
European urology, 63(3), 462-472. Elsevier

Background The optimal dose and duration of intravesical bacillus Calmette-Guerin (BCG) in the treatment of non–muscle-invasive bladder cancer (NMIBC) are controversial. Objective To determine if a one-third dose (1/3D) is not inferior to the full

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::602298eef40381f428c6c8aa0959d0eb
https://doi.org/10.1016/j.eururo.2012.10.039

European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG)

Autor: N. Nicolai, O. Leiva, Johnathan K Joffe, O. Klepp, P. Walz, Rolf Mueller, M. de Wit, S. Clemm, S. D. Fossa, Niels E. Skakkebæk, Gedske Daugaard, Robert Huddart, S. Tjulandin, M. Kuczyk, S. Krege, M. D. Mason, G. Kaiser, X. Garcia del Muro, László Kisbenedek, Gosse O N Oosterhof, O. Rick, Wolfgang Hoeltl, S. Kliesch, H. von der Maase, M. Bamberg, A. Gerl, N. Aass, Christian Kollmannsberger, G. Pizzocaro, M. Hartmann, L. Weissbach, O. Pont, U. Studer, P. Albers, M.P. Laguna, V. Loy, R. Souchon, H.-J. Schmoll, J. P. Droz, P.H.M. de Mulder, Heinz Schmidberger, Jörg Beyer, K. Fizazi, Tobias Pottek, J. Classen, G. M. Mead, Alan Horwich, L. Paz Ares, C. Bokemeyer, W. Jones, Eva Winter, T. Oliver, H. G. Derigs, J. R. Germa-Lluch, Felix Sedlmayer, István Bodrogi, Stefan Weinknecht, M. Flasshove, A. Heidenreich, F. Algaba, R. de Wit, S. Culine, K. U. Koehrmann, C. Wittekind, J. T. Hartmann, K. P. Dieckmann, W. Siegert, G. Rosti

Publikováno v: Annals of Oncology, 15, 9, pp. 1377-99
Annals of Oncology, 15, 1377-99
Annals of Oncology, 15, 1377-1399. Elsevier Ltd.
Schmoll, H J, Souchon, R, Krege, S, Albers, P, Beyer, J, Kollmannsberger, C, Fossa, S D, Skakkebaek, N E, de Wit, R, Fizazi, K, Droz, J P, Pizzocaro, G, Daugaard, G, de Mulder, P H, Horwich, A, Oliver, T, Huddart, R, Rosti, G, Paz Ares, L, Pont, O, Hartmann, J T, Aass, N, Algaba, F, Bamberg, M, Bodrogi, I, Bokemeyer, C, Classen, J, Clemm, S, Culine, S, de Wit, M, Derigs, H G, Dieckmann, K P, Flasshove, M, Garcia del Muro, X, Gerl, A, Germa-Lluch, J R, Hartmann, M, Heidenreich, A, Hoeltl, W, Joffe, J, Jones, W, Kaiser, G, Klepp, O, Kliesch, S, Kisbenedek, L, Koehrmann, K U, Kuczyk, M, Laguna, M P, Leiva, O, Loy, V, Mason, M D, Mead, G M, Mueller, R P, Nicolai, N, Oosterhof, G O, Pottek, T, Rick, O, Schmidberger, H, Sedlmayer, F, Siegert, W, Studer, U, Tjulandin, S, Maase, H V D, Walz, P, Weinknecht, S, Weissbach, L, Winter, E & Wittekind, C 2004, ' European consensus on diagnosis and treatment of germ cell cancer : A report of The European Germ Cell Cancer Consensus Group (EGCCCG) ', European Urology, vol. 15, pp. 1377-1399 .

Germ cell tumour is the most frequent malignant tumour type in young men with a 100% rise in the incidence every 20 years. Despite this, the high sensitivity of germ cell tumours to platinum-based chemotherapy, together with radiation and surgical me

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::03402bbd11b08d48e88c2f718a1ae54e
https://doi.org/10.1093/annonc/mdh301

Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guérin, and bacillus Calmette-Guérin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder

Autor: Cees van de Beek, Wim J. Kirkels, Ziya Kirkali, Theo M. de Reijke, Richard J. Sylvester, Wolfgang Hoeltl, Thierry Gorlia, Philip Powell, Maurizio A. Brausi, Stephen Prescott, Fernando Calais da Silva

Publikováno v: European Urology, 57(5), 766-773. Elsevier
European urology, 57(5), 766-773. Elsevier

Background: Intravesical chemotherapy and bacillus Calmette-Guerin (BCG) reduce the recurrence rate in patients with stage Ta T1 urothelial bladder cancer; however, the benefit of BCG relative to chemotherapy for long-term end points is controversial

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::09ed7c0b67b67625e7dbd4b7956eb971
https://pubmed.ncbi.nlm.nih.gov/21531192

Renal Vein Anatomy and its Implications for Retroperitoneal Surgery

Autor: Wolfgang Hoeltl, Walter Hruby, Seyedhossein Aharinejad

Publikováno v: Journal of Urology. 143:1108-1114

Because of its complicated embryological development, the anatomy of the renal veins shows extensive variability. A full understanding of the potential anatomical variations is imperative for retroperitoneal operations. Based on 4,520 retroperitoneal

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::063088325496c54bba317ef2578a420b
https://doi.org/10.1016/s0022-5347(17)40199-6

The side effects of Bacillus Calmette-Guerin in the treatment of Ta T1 bladder cancer do not predict its efficacy: results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III Trial

Autor: Richard Sylvester, W. Oosterlinck, Wolfgang Hoeltl, Adrian P.M. van der Meijden, Aldo V. Bono

Publikováno v: European urology. 44(4)

Objectives: Previous publications have suggested that patients developing local and/or systemic side effects to Bacillus Calmette-Guerin (BCG) have a better clinical result, however it is necessary to determine if toxicity is responsible for improved

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e6151a8192f33cefa9f3dd29a9c64cc5
https://pubmed.ncbi.nlm.nih.gov/14499675